UNCY Unicycive Therapeutics, Inc.

Unicycive Therapeutics Inc is a biotechnology company dedicated towards developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.

$1.84
As of 12/06/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/17/2021
Outstanding shares:  14,972,552
Average volume:  164,292
Market cap:   $29,945,104
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    90466Y103
ISIN:        US90466Y1038
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   1.43
PS ratio:   0.00
Return on equity:   -42.88%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy